Steroids · 2025
Evaluation of the diagnostic value of G protein-coupled estrogen receptor (GPER) in COVID-19 cases at Tokat Province.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guzelgul Figen, Kurutas Ergul Belge
Аннотация
OBJECTIVE: Factors affecting the clinical course of COVID-19, an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, are still poorly understood. G protein-coupled estrogen receptor (GPER) is a protein encoded by the GPER gene in humans. GPER is activated by binding to estradiol, a female sex hormone, leading to mediation of estradiol's rapid cellular effects. In this study, which was conducted for the first time, we aimed to investigate GPER levels and their diagnostic value in COVID-19 patients.
METHODS: A total of 71 individuals [Female/Male (n = 36/35) range of ages 32 ∼ 62] were enrolled in this study and categorized into three groups: the patient group consisted of individuals diagnosed with COVID-19 and receiving supportive treatment in the intensive care unit (ICU), the mild group consisted of COVID-19 patients who received outpatient treatment, and the control group. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum GPER levels.
RESULTS: The general sex distribution of the patients was analyzed, revealing that 35(49.3 %) were male and 36(50.7 %) were female. GPER levels were significantly increased in severe COVID-19 females compared to control and mild course groups (p < 0.05). A GPER cut-off value of 2.95 ng/mL showed diagnostic accuracy in severe COVID-19 cases.
CONCLUSION: This study, conducted for the first time, demonstrates that GPER levels are significantly associated with COVID-19 severity in female patients, suggesting that GPER may serve as a diagnostic marker for the progression of COVID-19.
METHODS: A total of 71 individuals [Female/Male (n = 36/35) range of ages 32 ∼ 62] were enrolled in this study and categorized into three groups: the patient group consisted of individuals diagnosed with COVID-19 and receiving supportive treatment in the intensive care unit (ICU), the mild group consisted of COVID-19 patients who received outpatient treatment, and the control group. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum GPER levels.
RESULTS: The general sex distribution of the patients was analyzed, revealing that 35(49.3 %) were male and 36(50.7 %) were female. GPER levels were significantly increased in severe COVID-19 females compared to control and mild course groups (p < 0.05). A GPER cut-off value of 2.95 ng/mL showed diagnostic accuracy in severe COVID-19 cases.
CONCLUSION: This study, conducted for the first time, demonstrates that GPER levels are significantly associated with COVID-19 severity in female patients, suggesting that GPER may serve as a diagnostic marker for the progression of COVID-19.